Essential Partners’s Atossa Therapeutics ATOS Stock Holding History

Essential Partners’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$12	–	2677
2025 Q2	$12	Buy	+1	New	+$12	﹤0.01%	2244

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Essential Partners's ATOS Position: Q3 2025 in Review

Essential Partners sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 1 share — an estimated $12 sold.

Essential Partners first reported a position in ATOS in Q2 2025 and held it in 1 quarter. The position peaked at $12 in Q2 2025. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

Essential Partners reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 1 Atossa Therapeutics share in Q3 2025, an estimated $12.
Essential Partners first reported a position in Atossa Therapeutics in Q2 2025 and held it in 1 quarter.
Essential Partners's Atossa Therapeutics position peaked at $12 in Q2 2025.
66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.